What do systematic reviews say?

Fluoxetine vs tianeptine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 730 participants
  Moderate

Fluoxetine vs tianeptine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with tianeptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.96 [0.69, 1.33]
  3 studies · 830 participants
  Moderate

Fluoxetine vs tianeptine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with tianeptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.82 [0.27, 2.53]
  3 studies · 830 participants
  Moderate

Fluoxetine vs agomelatine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1213 participants
  Moderate

Fluoxetine vs tianeptine

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with tianeptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.13 [0.71, 1.8]
  3 studies · 830 participants
  Moderate

Fluoxetine vs trazodone

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with trazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.49 [0.13, 1.86]
  3 studies · 110 participants
  Moderate

Fluoxetine vs trazodone

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 203 participants
  Moderate

Fluoxetine vs trazodone

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with trazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.51 [0.23, 1.13]
  4 studies · 230 participants
  Moderate

Fluoxetine vs trazodone

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with trazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.23 [0.04, 1.51]
  2 studies · 70 participants
  Moderate

Fluoxetine vs trazodone

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with trazodone (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.66 [0.2, 2.19]
  3 studies · 110 participants
  Moderate

Fluoxetine vs venlafaxine

Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with venlafaxine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.29 [1.1, 1.51]
  12 studies · 3387 participants
  Moderate

Fluoxetine vs venlafaxine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 3097 participants
  Moderate

Fluoxetine vs venlafaxine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with venlafaxine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.89 [0.74, 1.06]
  14 studies · 2683 participants
  Moderate

Fluoxetine vs venlafaxine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with venlafaxine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.31 [0.91, 1.89]
  13 studies · 2640 participants
  Moderate

Fluoxetine vs agomelatine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with agomelatine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.31 [0.89, 1.94]
  2 studies · 785 participants
  Moderate

Fluoxetine vs venlafaxine

Fluoxetine probably leads to lower failure to complete ‐ side effects ‐ compared with venlafaxine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.72 [0.56, 0.94]
  13 studies · 2640 participants
  Moderate

Fluoxetine vs agomelatine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with agomelatine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.08 [0.41, 2.88]
  2 studies · 785 participants
  Moderate

Fluoxetine vs agomelatine

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with agomelatine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.51 [0.74, 3.07]
  2 studies · 785 participants
  Moderate

Fluoxetine vs amineptine

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with amineptine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.37 [0.13, 1.04]
  1 study · 63 participants
  Moderate

Fluoxetine vs amineptine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported